| 國立成功大學 |
2015-10 |
At will or not at will: Electrophysiological correlates of preparation for voluntary and instructed task-switching paradigms
|
Chen, Poyu; Hsieh, Shulan |
| 國立臺灣體育運動大學 |
1989-05-02 |
AT&T網球賽 再遇剋星 張德培亞軍 稱讚阿格西打得好 往後的比賽有信心/天才之技 論張德培的球藝 馬克安諾的教練柯漢 在世界網球雜誌撰文 足以讓人一窺張德培撂倒名將的風貌……
|
劉延青 |
| 國立成功大學 |
2020-01-20 |
AT-3型機起落架減震支柱輕量化
|
吳鎮宇; Wu, Cheng-Yu |
| 國立成功大學 |
2019-12-24 |
AT-3型機起落架減震支柱輕量化
|
吳鎮宇; Wu, Cheng-Yu |
| 國立中山大學 |
2000 |
AT1及AT2接受器參與血管張力素抑制感壓反射作用之機轉研究(III)
|
陳慶鏗; Samuel H.H. Chan |
| 建國科技大學 |
2004 |
AT89S51/52 燒錄模擬器之設計
|
薛棟樑;羅榮村; Shiue Dong-Liang;Lou Rong-Tsuen |
| 國立臺灣科技大學 |
2003 |
ATA-based硬碟之效能監測系統之設計與實現
|
王佳 |
| 國立臺灣大學 |
1991 |
Ataxia-Telangiectasia Associated with Torticollis:Report of One Case
|
王本榮; Chu, J. M.; Tsai, Y. T.; Hseih, K. H.; Wang, Pen-Jung; Chu, J. M.; Tsai, Y. T.; Hseih, K. H. |
| 臺大學術典藏 |
2017 |
Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression
|
Lin, Been-Ren; Chen, Szu-Ta; Wu, Tai-Sheng; Cheng, Shih-Jung; Yang, Cheng-Ning; DENG, YI-TING; Kuo, Mark Yen-Ping; Chang, Cheng-Chi; WANG-TSO LEE; Li, Yue-Ju;Wang-Tso Lee;Chang, Cheng-Chi;Kuo, Mark Yen-Ping;Deng, Yi-Ting;Yang, Cheng-Ning;Cheng, Shih-Jung;Wu, Tai-Sheng;Chen, Szu-Ta;Lin, Been-Ren; Li, Yue-Ju |
| 臺大學術典藏 |
2021-07-05T05:41:55Z |
Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression
|
Li Y.-J.; Lai W.-T.; Chang C.-C.; YEN-PING KUO; Deng Y.-T.; Yang C.-N.; Cheng S.-J.; Wu T.-S.; Chen S.-T.; Lin B.-R. |
| 臺大學術典藏 |
2021-07-07T03:41:13Z |
Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression
|
Li Y.-J.; Lai W.-T.; Chang C.-C.; Kuo M.Y.-P.; Deng Y.-T.; Yang C.-N.; SHIH-JUNG CHENG; Wu T.-S.; Chen S.-T.; Lin B.-R. |
| 國立成功大學 |
2022 |
Ataxin-3蛋白表現在泌尿上皮癌的臨床意義
|
蔡育賢 |
| 國立成功大學 |
2021 |
Ataxin-3蛋白表現在泌尿上皮癌的臨床意義
|
蔡育賢 |
| 國立成功大學 |
2023 |
Ataxin-3蛋白表現在泌尿上皮癌的臨床意義
|
蔡育賢 |
| 國立臺灣師範大學 |
2014-10-27T15:41:56Z |
Atayal Myths
|
黃美金 |
| 國立臺灣師範大學 |
2015-01-29T09:15:36Z |
Atayal Reduplication and Its Interface with Phonology
|
林蕙珊 |
| 慈濟大學 |
2006 |
AtBAG-4在光敏素的訊息傳遞中所扮演的角色
|
鄭凱鴻 |
| 慈濟大學 |
2009 |
AtBAG4在種子及果實發育中所扮演的角色
|
林怡萱 |
| 朝陽科技大學 |
2018-05-31 |
ATC-水中運動椅
|
林志旻 |
| 國立交通大學 |
2014-12-12T02:29:34Z |
ATC公司在中國大陸研發投資之個案研究
|
溫斯成; Szu-Cheng Wen; 王 克 陸; Kehluh Wang |
| 元培科技大學 |
2009-04-24 |
Ate pairing效能改進之研究
|
林志賢 |
| 國立成功大學 |
2014-01 |
Atectonic Expression from Theory to Practice: From Semper's Bekleidung to Empirical Projects
|
Wu, Nan-Wei; Fu, Chao-Ching |
| 臺大學術典藏 |
2021-07-15T05:31:34Z |
Atelocollagen-embedded chondrocyte precursors as a treatment for grade-4 cartilage defects of the femoral condyle: A case series with up to 9-year follow-up
|
Liu, Hwa Chang; Liu, Tzu Shang Thomas; Liu, Yen Liang; JYH-HORNG WANG; Chang, Chih Hung; TIFFANY TING-FANG SHIH; Lin, Feng-Huei |
| 臺大學術典藏 |
2021-12-16T03:41:34Z |
Atelocollagen-Embedded Chondrocyte Precursors as a Treatment for Grade-4 Cartilage Defects of the Femoral Condyle: A Case Series with up to 9-Year Follow-Up
|
Liu, Hwa-Chang; Liu, Tzu-Shang Thomas; Liu, Yen-Liang; Wang, Jyh-Horng; Chang, Chih-Hung; TIFFANY TING-FANG SHIH; Lin, Feng-Huei |
| 臺大學術典藏 |
2022-03-22T08:28:54Z |
Atelocollagen-embedded chondrocyte precursors as a treatment for grade-4 cartilage defects of the femoral condyle: A case series with up to 9-year follow-up
|
Liu H.-C;Liu T.-S.T;Liu Y.-L;Wang J.-H;Chang C.-H;Shih T.T.-F;Lin F.-H.; Liu H.-C; Liu T.-S.T; Liu Y.-L; Wang J.-H; Chang C.-H; Shih T.T.-F; Lin F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2022-03-22T08:32:04Z |
Atelocollagen-embedded chondrocyte precursors as a treatment for grade-4 cartilage defects of the femoral condyle: A case series with up to 9-year follow-up
|
Liu H.-C;Liu T.-S.T;Liu Y.-L;Wang J.-H;Chang C.-H;Shih T.T.-F;Lin F.-H.; Liu H.-C; Liu T.-S.T; Liu Y.-L; Wang J.-H; Chang C.-H; Shih T.T.-F; Lin F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2022-03-22T08:31:57Z |
Atelocollagen-embedded chondrocyte precursors as a treatment for grade-4 cartilage defects of the femoral condyle: A case series with up to 9-year follow-up
|
Liu H.-C;Liu T.-S.T;Liu Y.-L;Wang J.-H;Chang C.-H;Shih T.T.-F;Lin F.-H.; Liu H.-C; Liu T.-S.T; Liu Y.-L; Wang J.-H; Chang C.-H; Shih T.T.-F; Lin F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2021-08-10T03:37:24Z |
Atelocollagen-Embedded Chondrocyte Precursors as a Treatment for Grade-4 Cartilage Defects of the Femoral Condyle: A Case Series with up to 9-Year Follow-Up
|
Liu, Hwa-Chang; Liu, Tzu-Shang Thomas; Liu, Yen-Liang; JYH-HORNG WANG; Chang, Chih-Hung; Shih, Tiffany Ting-Fang; Lin, Feng-Huei |
| 國立臺灣大學 |
1952 |
Atempt to Synthesige 5.6.7.8.2'.3'.4'.5'.6'-Nonahydroxyflavone
|
廖宗凱 |
| 臺北醫學大學 |
1994 |
Atenolol前驅藥之製備研究
|
林友慈 |
| 臺北醫學大學 |
2004 |
Atenolol與Carvedilol於高血壓大白鼠大動脈內皮細胞隙連結之差異性作用
|
李秉穎; Ping-Ying Lee |
| 國立臺灣大學 |
2010 |
AtERF1及AIL7在非生物性逆境耐受性上分別扮演的角色
|
郭瑋文; Kuo, Wei-Wen |
| 朝陽科技大學 |
2022-12-09 |
ATERRA
|
陳奕如;潘妏婷;李岱樺;蔡宜軒;張雨薇;黃沛儒 |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
|
Finn R.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-14T23:18:53Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:02Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang Y.; Lu L.-C.; Guan Y.; Ho M.-C.; Lu S.; Spahn J.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-11-25T02:38:28Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li-Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; Hsu, Chih-Hung |
| 國家衛生研究院 |
2021-07 |
Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load
|
Chen, S;Lai, H;Tsou, H;Shao, Y;Chang, C;Su, T;Liu, T;Chen, L;Cheng, A;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Chih-Hung Hsu;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chih-Hung Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIH-HUNG HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 國家衛生研究院 |
2025-01 |
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
|
Wu, SG;Ho, CC;Yang, JC;Yu, SH;Lin, YF;Lin, SC;Liao, BC;Yang, CY;Lin, YT;Yu, CJ;Chuang, YT;Liao, WY;Yap, KY;Kou, WS;Shih, JY |
| 臺北醫學大學 |
2014 |
ATF3 PROTECT AGAINST PRESSURE OVERLOAD HEART FAILURE VIA BECLIN-1 PATHWAY
|
Cheng, C.F.;Li, S.F.;Lin, H. |
| 臺北醫學大學 |
2013 |
ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression
|
PF, Lia;CF, Cheng;Lin, H;TL, Tseng;HH, Chen;SH, Chen |
| 臺北醫學大學 |
2013 |
ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression
|
Lia, PF;Cheng, CF;Lin, H;Tseng, TL;Chen, HH;Chen, SH |
| 臺北醫學大學 |
2014 |
ATF3 Protects Against Pressure Overload Heart Failure Via Autophagy Molecule Beclin-1 Pathway
|
Lin, H;Li, HF;Chen, HH;Lai, PF;Juan, SH;Chen, JJ;Cheng, CF. |
